The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

affinergy.com

Founded Year

2003

Stage

Grant | Alive

Total Raised

$7.07M

Last Raised

$70K | 6 yrs ago

About Affinergy

Affinergy develops site-specific biological delivery systems using biofriendly binders that can selectively adhere to proteins, cells and other biomaterial surfaces. Affinergy's multifunctional delivery systems offer unprecedented opportunities to target therapeutic delivery, functionalize medical devices, and enable a variety of diagnostic and biosensor applications. Affinergy is a Duke University spin-out company being incubated by BD (Becton, Dickinson and Company) and is headquartered in Research Triangle Park, NC. IDEA Fund Partners was an investor in the company's Series A financing.

Affinergy Headquarter Location

617 Davis Drive Suite 100

Durham, North Carolina, 27713,

United States

919-433-2200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Affinergy

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Affinergy is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,082 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,900 items

Affinergy Patents

Affinergy has filed 19 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/24/2014

3/8/2016

Endocrine system, Human cells, Thyroid, Glands, Adrenal gland

Grant

Application Date

10/24/2014

Grant Date

3/8/2016

Title

Related Topics

Endocrine system, Human cells, Thyroid, Glands, Adrenal gland

Status

Grant

Affinergy Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Affinergy Rank

  • When was Affinergy founded?

    Affinergy was founded in 2003.

  • Where is Affinergy's headquarters?

    Affinergy's headquarters is located at 617 Davis Drive, Durham.

  • What is Affinergy's latest funding round?

    Affinergy's latest funding round is Grant.

  • How much did Affinergy raise?

    Affinergy raised a total of $7.07M.

  • Who are Affinergy's competitors?

    Competitors of Affinergy include Integrated Nano-Technologies, Mercator MedSystems, Celsense, ContraVac, Imarad Imaging Systems and 11 more.

You May Also Like

R
Rafael Medical Technologies

Rafael Medical has developed a novel anchoring system for safely implanting and retrieving a wide range of intra-vascular devices in a minimally invasive manner. Based on the technology, diagnostic and therapeutic devices can be delivered into small and large blood vessels alike by way of a small-sized delivery system. Following the completion of the SafeFlo Filter the company is now developing additional devices geared to the interventional cardiology market.

InPhenix Logo
InPhenix

InPhenix is a developer and manufacturer of optoelectronic devices for the medical, defense, and telecom markets. The company's Super Light Emitting Diodes (SLEDs) are utilized in a variety of optical imaging systems for biomedical applications, and its customers include several leading manufacturers of ophthalmic and laboratory diagnostic instrumentation.

M
Mediguide

MediGuide is a medical-device company developing tracking and imaging technologies for use during minimally-invasive surgical procedures. Located in Haifa, Israel, MediGuide was established in 2001 as a spin-off of Elbit Systems (NASDAQ: ESLT), a major Israeli defense technology company. MediGuide has developed a highly sophisticated navigation system: Medical Positioning System ("gMPS"), which is aimed to enable real-time tracking of therapeutic and future diagnostic medical devices (gMPS Enabled Devices) such as catheters and stents equipped with miniature gMPS sensors. gMPS is intended to provide clinicians with 3-D information about the structure of the coronary arteries and to track gMPS-enabled devices in these vessels.

Proterixbio Logo
Proterixbio

ProterixBio develops products to transform the management of chronic diseases.

M
Mercator MedSystems

Mercator MedSystems has developed a broad-based therapeutic platform that allows clinicians to accurately and efficiently deliver drugs and biologics such as stem cells to tissues deep in the body, treating the root cause of significant medical conditions. The company utilizes its family of Micro-Infusion Catheters for targeted treatments via the vascular system, including peripheral artery disease (PAD) and resistant hypertension (HTN); and via the bronchial tree, including malignant airway obstruction secondary to lung cancer. The company's 510(k)-cleared and CE-Marked Cricket and Bullfrog Micro-Infusion Catheters are vascular-access systems that are able to inject drugs, genes, and cells safely through vessel walls into deep tissues without major surgery.

i
iMMCO Diagnostics

IMMCO Diagnostics provides high-quality diagnostic test kits and lab testing services worldwide for the screening of autoimmune disorders. IMMCO Diagnostics incorporates working on research, clinical laboratory expertise, and medical devices into an approach to autoimmune diagnostics.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.